Endocyte (ECYT) Removed from Wedbush's Best Ideas List
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- US stock futures little changed as strong quarter nears end
- Strong dollar pushes yen to 40-year low as traders test Japanese authorities
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Endocyte Reports First Quarter Financial Results and Provides Clinical Update
May 2, 2014 8:01 AM EDT- Independent DSMB Recommends to Stop Phase 3 PROCEED Trial for Futility Following Interim Analysis
- Endocyte Initiates Phase 1 Trial of PSMA-Targeted Tubulysin SMDC (EC1169) in Prostate Cancer Following FDA Acceptance of IND
- Conference Call Today at 8:30 a.m. EDT
WEST LAFAYETTE, Ind., May 2, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq: ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy,... More
